Investigating a targeted therapy for chronic lymphocytic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug that targets a protein called IRAK4, which is involved in the growth of cancer cells in chronic lymphocytic leukemia (CLL). The goal is to see if this treatment can help people with CLL.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL).
- You must be willing and able to provide informed consent to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
This study follows people newly diagnosed with chronic lymphocytic leukemia (CLL), a type of blood cancer, to learn more about the disease and how it progresses. By participating, you help researchers understand CLL better, which may improve future treatments.
This study uses advanced 3D lab models to test personalized treatments for certain types of blood cancer (CLL, SMZL, HCL). It aims to find better ways to use immunotherapy and combination therapies for each patient.
This trial tests a combination of three drugs—roginolisib, obinutuzumab, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to previous treatment. The goal is to see if this combination can help control the disease.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This study looks at how well a type of targeted therapy called a BTK inhibitor works for people with chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow. It includes both people who have never been treated and those whose cancer came back or didn't get better. The goal is to understand real-world outcomes and help guide future care.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.